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Abstract
For more than a decade human papillomavirus (HPV) vaccine have been implemented in most high-income
countries, and more recently also in several low- and middle-income countries. The vaccines are safe and their
impact and effectiveness in preventing HPV vaccine type infection and associated diseases has been thoroughly
established. Currently, the primary recommended cohorts for immunisation are adolescents, 9–15 years of age but
HPV is an ubiquitous infection that is mainly (but not exclusively) sexually transmitted. Sexually active adults remain
susceptible to infection and continued transmission of the virus, representing a reservoir of infection in the
population. A recent meeting, conducted by the HPV Prevention and Control Board (HPV-PCB), reviewed the
current status of HPV vaccination of adults, discussed limitations, challenges and benefits of HPV vaccination of
adults, evaluated the effectiveness of HPV vaccination after treatment of post cervical cancer and precancerous
lesions, and discussed the potential impact of adult vaccination on cervical cancer elimination strategies in light of
the current and future HPV vaccine shortage. HPV-PCB is an independent multidisciplinary board of international
experts that disseminates relevant information on HPV to a broad array of stakeholders and provides guidance on
strategic, technical and policy issues in the implementation of HPV prevention and control programs. The HPV-PCB
concluded that, given the current data available on adult HPV vaccination and the ongoing vaccine supply
constraints, it is too early to implement routine vaccination of adults. Many research gaps need to be filled before
we have a better understanding of the efficacy and broader public health impact of HPV vaccination in adult
women.
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Background
The Human Papillomavirus (HPV) Prevention and Con-
trol Board (www.hpvboard.org) (HPV-PCB) is an inter-
national independent multidisciplinary board that was
created in 2015 [1]. The HPV-PCB is a group of experts
who provide evidence-based guidance on strategic, tech-
nical and policy issues that occur as part of the imple-
mentation of HPV control programmes. The HPV-PCB
aims to generate and disseminate relevant information
on prevention and control of HPV-associated diseases to
a broad array of stakeholders. It achieves its objectives
by organizing two meetings per year [1–5]. One is a
technical meeting covering topics such as vaccine effi-
cacy, vaccine safety, screening technologies and policies,
treatment strategies, and approaches to address vaccine
hesitancy. The second meeting is a country-specific
meeting covering a Strength, Weakness, Opportunities
and Threats (SWOT) analysis of a country or region.
This report covers the seventh meeting of the HPV-PCB
held in Antwerp, Belgium (12–13 November 2019): a
technical meeting on challenges, impact and opportun-
ities for HPV vaccination in adults.
HPV vaccines have been implemented in the National
Immunization Programmes (NIPs) of several high-
income countries (HICs) for 10 years or more. These
vaccines are safe, and their impact and effectiveness in
preventing vaccine-type HPV infection and associated
diseases are scientifically confirmed. Currently, the rec-
ommended cohorts for immunisation are adolescents 9–
15 years of age, since HPV vaccines are prophylactic and
confer protection to infection before the onset of sexual
activity. Unvaccinated sexually active adults remain sus-
ceptible to infection and contribute to transmission, thus
representing a reservoir of infection in the population.
Immunisation of older cohorts could potentially restrict
HPV transmission and thus contribute to reducing infec-
tion prevalence, which would accelerate the population
impact of these vaccines on both benign and malignant
HPV-associated diseases. However, there is limited evi-
dence to support these assertions and the question is
what the magnitude of this transmission might be and
how cost-effective vaccination would it be to prevent it.
The meeting was held to address the following issues:
 To provide an overview of the current status of
HPV vaccination in adults.
 To review the immunogenicity, safety and efficacy
data from existing studies on HPV vaccination in
adult women.
 To gain insight into the efficacy of the HPV vaccine
at the mucosal and systemic levels
 To discuss ways and methods to conduct effective
research on the potential benefits of vaccinating
adults likely to have prior genital exposure to HPV
 To discuss challenges and benefits of vaccination in
adults, including high-risk groups.
 To discuss cervical cancer elimination strategies and
the impact of adult vaccination on elimination
strategies
 To discuss the potential implication of vaccination
in adults on vaccine supplies in low- and middle-
income countries (LMICs)
This report summarizes the discussions and lessons
learned from the participants.
Situational analysis of HPV vaccination in adults:
immunogenicity and safety data
Efficacy and safety of prophylactic HPV vaccination in
adults
The results of the recent Cochrane review by Arbyn
et al. were discussed [6]. The review evaluated the risks
and benefits of prophylactic HPV vaccines against cer-
vical precancer lesions and HPV-16/18 infection in ado-
lescent girls and women, including randomised
controlled trials (RCTs) comparing efficacy and safety in
females offered an HPV vaccine or placebo (vaccine ad-
juvants or another control vaccine). The study included
data from 26 trials, of which three recruited women aged
25 and over. The effects of the vaccines in participants
who had at least one vaccine dose were summarized [6].
There is high-certainty evidence that HPV vaccines
protect against cervical precancer lesions in adolescent
girls and young women aged 15 to 26 years. The effect is
higher for lesions associated with HPV-16/18 than for
lesions irrespective of the HPV type. The effect is greater
in those who are negative for high risk HPV (hr)HPV)
or HPV-16/18 DNA at enrolment than in those
unselected for the HPV DNA status. There is moderate-
certainty evidence that HPV vaccines reduce the inci-
dence of cervical intraepithelial neoplasia (CIN) grade
2+ in older women who are HPV-16/18-negative but
not when they are unselected by the HPV DNA status
[6]. Similarly, in a nested case-control study of women
enrolled in Kaiser Permanente Northern California with
women with CIN2+ or CIN3+ as cases and age-matched
women without CIN2+ or CIN3+ as controls, the stron-
gest protection against CIN2+ was found in women who
had received their first dose between the age of 14 and
17 years (relative risk (RR) 0.52, 95% confidence interval
(CI) 0.36–0.74) or 18 and 20 years (RR 0.65, 95% CI
0.49–0.88) [7]. No significant protection was found in
women aged 21 years or older at their first dose (RR
0.94, 95% CI 0.81–1.09). Similar results were obtained
for CIN3+ with the first dose at ages 14–17 years (RR
0.27, 95%CI 0.13–0.56) or ages 18–20 years (0.59, 95%CI
0.36–0.97), leading to the conclusion that catch-up
quadrivalent HPV vaccination with quadrivalent vaccine
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was effective against CIN2+ and CIN3+ in girls and
women aged 14–20 years at the time of the first vaccine
dose but not for women aged 21 years and older at the
first dose [7].
Based on four RCTs in adult women, two with the bi-
valent vaccine and two with the quadrivalent vaccine, no
increased risk of serious adverse effects (RR = 1.05, 95%
CI 0.91–1.21) was observed [6].
Immunogenicity and tolerability of the HPV vaccine in
women aged 15–55 years
A long-term follow-up study (NCT00947115) of females
aged between 15 and 55 years at first vaccination with
the bivalent HPV vaccine was discussed [8]. Participants
in the primary phase III study (NCT00196937) were in-
vited to attend annual evaluations of long-term im-
munogenicity and safety. Anti-HPV-16/18 antibodies in
serum and cervicovaginal secretions (CVS) were mea-
sured using an enzyme-linked immunosorbent assay
(ELISA). Seropositivity rates for anti-HPV-16 remained
high (≥96.3%) in all age groups 10 years after the first
vaccination, whereas seropositivity for anti-HPV-18 de-
creased from 99.2% in 15 to 25 year olds to 93.7 and
83.8% in 26 to 45 year olds and 45 to 55 year olds, re-
spectively [8]. Nevertheless, geometric mean titres
remained above natural infection levels in all age groups:
anti-HPV-16 and anti-HPV-18 titres were at least 5.3-
fold and 3.1-fold higher than titres observed after natural
infection, respectively, and were predicted to persist
above natural infection levels for at least 30 years in all
age groups [8].
Correlation coefficients for antibody titres in serum
and CVS were 0.64 (anti-HPV-16) and 0.38 (anti-HPV-
18), suggesting the transudation of antibodies to the cer-
vical epithelium.
Serious adverse events (SAEs) were recorded through-
out the follow-up period. Two deaths occurred in the
vaccinated cohort, and both were considered not to be
vaccine related [8].
It was concluded that vaccination in females aged 15–
55 years elicited sustained immunogenicity with an ac-
ceptable safety profile up to 10 years after the primary
vaccination, suggesting long-term protection against
HPV.
A head-to-head study (NCT00423046) of three doses
of the bivalent and quadrivalent HPV vaccines in healthy
women aged 18–45 years showed that 5 years after vac-
cination, the serum neutralizing antibody responses in-
duced by the bivalent vaccine remained 7.8-fold (18–26-
years stratum), 5.6-fold (27–35-years stratum) and 2.3-
fold (36–45-years stratum) higher than those induced by
the quadrivalent vaccine for HPV-16. For HPV-18, the
fold differences were 12.1, 13.0 and 7.8, respectively [9].
HPV immunological dynamics at the mucosal and
systemic levels
Immune crosstalk of the HPV-specific antibody response:
cross-reactivity, neutralizing activity, mucosal secretion
and infection prevention
To investigate antibody seroprevalences of 7 hr-HPV ge-
notypes (HPVs 16, 18, 31, 33, 45, 52, and 58) in two
sero-surveys among the Dutch general population in the
pre-vaccination era, serum samples of men and women
(0–79 years of age; 1995–96 n = 3303; 2006–07 n =
6384) were tested for anti-HPV-specific antibodies in a
virus-like particle (VLP)-based multiplex immunoassay
[10]. A higher overall seroprevalence in individuals older
than 15 years of age was found for HPV 16, 18, 31 and
45 in 2006–07 than 1995–96. Seropositivity for one or
more HPV types (2006–07, 23.1%; 1995–96, 20.0%; p =
0.013) and multi-seropositivity (2006–07, 10.2%; 1995–
96, 7.1%; p < 0.0001) increased [10]. The observed in-
crease in specific HPV-16 seroprevalence was most likely
due to changes in sexual behaviour, especially in the age
of sexual debut.
Data were also shown that extended the study to a
new sero-survey performed in 2016, 6 years after the
introduction of the bivalent HPV vaccine to the National
Immunization Programme in the Netherlands. After
adjusting for demographic characteristics and sexual risk
factors, a consistently lower seroprevalence of HPV16 in
men (adjusted prevalence ratio (PR) = 0.7, 95% CI 0.5–
0.9) was shown. In contrast, a higher seroprevalence was
observed in females for HPV16 (1.3; 1.0–1.6), HPV18
(1.8; 1.3–2.3) and any HPV type (1.2; 1.0–1.3) [11].
Nevertheless, a large part of the population was sero-
negative. At 12 and 24months, after the vaccination,
Immunoglobulin G (IgG) antibodies could be detected
in cervical secretions against HPV types 16, 18, 31, 33,
52 and 58. The correlation coefficients for antibodies in
serum and CVS at 12 months were 0.58 for HPV-16 and
0.50 for HPV-18 [12].
Humoral and cellular immune responses were evalu-
ated after different doses of the bivalent (2v) HPV vac-
cine in girls [13]. Blood was collected annually until 7
years post-vaccination with one, two or three doses of
the vaccine (N = 890). HPV-type-specific IgG and Im-
munoglobulin (IgA) antibody levels, IgG isotypes and
avidity indexes were measured by a VLP-based multiplex
immunoassay for two vaccine and five non-vaccine HPV
types. HPV-type-specific memory B cell numbers and T
cell cytokine responses were determined in a subpopula-
tion. HPV type-specific antibody concentrations were
significantly lower in girls vaccinated with one dose than
in girls vaccinated with two or three doses but remained
stable over 7 years. The lower antibody response coin-
cided with reduced HPV type-specific B and T cell re-
sponses. There were no differences in either the IgG
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subtypes or the avidity of the HPV-16-specific antibodies
between the groups [13]. Differences between immune
responses generate by the bivalent and quadrivalent
HPV vaccines have been reported [14]. Currently, a
study is ongoing to look at early differences in immune
responses between bivalent and nonvalent HPV vaccines.
Adult women (n = 20, 23–46 years of age, seronegative
for HPV types 16, 18, 31, 33, 45, 52 and 58) were vacci-
nated at baseline, month 2 and month 6, and blood sam-
ples were taken at baseline and days 1, 2, 3, 6, 7, 10, and
14, 6 months, 6 months + 1 day, 6 months + 3 days, 6
months + 7 days, and 6 months + 28 days. These samples
were subjected to an in-depth analysis of up to 250 in-
nate and adaptive immune cell subsets with high-
throughput flow cytometry [15], specific antibody levels
were analysed by a VLP-based multiplex immunoassay
and specific memory B and T cell responses were deter-
mined by enzyme-linked immune absorbent spot (ELI-
Spot) assays. Preliminary results revealed the early
expansion of several innate cell subsets at day 1. This ex-
pansion was followed by a T cell response at day 3. All
donors showed a clear expansion of plasma cells, which
were mostly of the IgG1 isotype, at day 7 post-
vaccination. Further studies are needed to investigate
whether early immune responses predict long-term anti-
body levels.
Vaccine-induced HPV-specific antibodies in CVS
Because HPV infects the cervical mucosal epithelium,
measuring cervical immunity is important for evaluating
local immune responses to HPV infection and vaccin-
ation. Neutralizing antibodies are presumably the main
effectors of protection against HPV infection and pre-
vent the initial entry of the virus into basal epithelial
cells. Humoural responses are most frequently detected
in serum, whereas immune responses in CVS are usually
not investigated.
Measurements of local immune responses at the cervix
have been hampered by the difficulty in reliably collect-
ing female genital secretions for immunological evalua-
tions and in standardizing sampling to assess the
variation in levels of total transudated IgG in the secre-
tion across the menstrual cycle. Most CVS were col-
lected by cervicovaginal lavage, during which the vaginal
vault was rinsed with washing buffer. This results in
sample dilution, which may complicate antibody detec-
tion. Alternatively, cervicovaginal wicks are also fre-
quently used. These sponges, which are inserted in the
vagina, passively absorb CVS. However, the application
of wicks may result in microtrauma, potentially causing
blood contamination and making the samples unsuitable
for the detection of mucosal antibodies [16]. Alternatives
for collection might be a soft cup [17] or the use of first-
void urine [18].
It was concluded that antibody detection of anti-HPV
antibody in CVS is feasible, although the concentration
is considerably lower than that of systemic antibodies in
blood. However, the high variability and the lack of a
strictly uniform, well-validated method for the collec-
tion, sample preparation, detection and quantification of
anti-HPV-specific antibodies at the cervix indicate the
need for specific methods that can improve and
standardize detection. Furthermore, heterogeneity in
absorbed and extracted sample volumes requires
normalization to allow valid inter-individual compari-
sons [16].
Most studies showed a moderate to strong correlation
between anti-HPV-16/18 antibody levels in serum and
CVS, indicating that vaccine-induced anti-HPV anti-
bodies transudate from blood vessels to the cervical
mucosa. The key question remains whether these
transudated antibodies are needed to protect against
transmission or whether exudation of systemic anti-
bodies from blood at the sites of trauma where infec-
tions are initiated (discussed below) are sufficient.
Studies are needed to clarify this point.
Challenges and potential benefits of HPV
vaccination in adults
Pap smear collection: an increased risk of HPV infection?
An objective study in a rhesus macaque model
Many features of HPV infection are still poorly under-
stood. Productive papillomavirus infection is species-
and tissue-restricted, and traditional models use animal
papillomaviruses that infect the skin or oral mucosa. A
mouse model of cervicovaginal infection with HPV16
was developed that recapitulates the establishment phase
of papillomavirus infection. However, for infection to
occur, disruption of the integrity of the stratified or col-
umnar genital epithelium, either via chemical disruption
or Cytobrush treatment, was required [19]. This led to
the hypothesis that Pap smear collection, which also
breaches the epithelium, may facilitate dissemination of
HPV infection. This was tested in female rhesus ma-
caques by performing a speculum examination with or
without a cytology specimen collection procedure using
a plastic spatula [20]. An internal digital examination
was performed after specimen collection using Surgilube
or carrageenan, a previously identified HPV inhibitor
[21], as lubricant. The substantial infection of the ecto-
cervix, the transformation zone, and the endocervix was
detected, but only in conjunction with the cytology spe-
cimen collection procedure (1000 times higher infection
rate than the control). When carrageenan gel was used
as a lubricant for an internal digital examination, the
number of infectious events decreased by approximately
95%. This suggests that cytology screening in women
might lead to a transient enhancement of susceptibility
Waheed et al. BMC Proceedings 2021, 15(Suppl 7):16 Page 4 of 15
to HPV infection and that the use of a carrageenan-
based gel during the examination might mitigate this en-
hancement [20]. However, it was concluded that current
cervical cytology sampling procedures are justified [22]
because the wide use of organized screening pro-
grammes has decreased the rates of cervical squamous
cell carcinoma, although not of the less frequent cervical
adenocarcinomas.
The efficacy of carrageenan in reducing the risk of
genital HPV infections is currently being studied in clin-
ical trials, e.g., the LIMIT-HPV study (NCT02354144).
An interim analysis of a randomized, double-blind,
placebo-controlled, phase 2B trial in women (ISRC
TN96104919) was recently published [23]. After a me-
dian follow-up time of 9.2 months, a total of 59 (42%) of
139 women in the carrageenan arm and 78 (57%) of 138
women in the placebo arm became DNA positive for at
least one new HPV type (hazard ratio (HR) = 0.64, 95%
CI = 0.45–0.89, p 0.009) [23].
HPV vaccine post-treatment: a pathway to prevent
disease relapse
A population-based cohort study conducted in Sweden
between 1958 and 2008 showed that women previously
diagnosed and treated for CIN3 had an increased risk of
death from invasive cervical or vaginal cancer compared
with the general female population [24]. Similarly, the
Study of the Prevention of Anal Cancer, a 3-year pro-
spective study of the natural history of anal HPV infec-
tion in men who have sex with men (MSM) who are at
least 35 years old, showed that the baseline rate of histo-
logical high-grade squamous intraepithelial lesion (HSIL)
diagnosis after HSIL cytology is high and increases with
further examinations over the course of 12 months [25].
Persistence of HPV infection after treatment is prob-
ably one of the most important factors predisposing pa-
tients to the persistence or recurrence of cervical lesions.
Other factors are also involved in the risk, such as the le-
sion size, residual disease in the margins of excisional
loop electrosurgical excision procedure (LEEP) speci-
mens, age of the patient, parity, and immunological sta-
tus [26, 27].
Although HPV vaccination has not shown therapeutic
effects in patients with pre-existing infection, recent data
suggest that vaccination may reduce the risk of recur-
rence of cervical lesions. A total of 587 vaccine and 763
placebo recipients from the FUTURE I and II studies of
the quadrivalent vaccine underwent excisional procedure
during follow-up. Vaccination was associated with a sig-
nificant reduction of 64.9% in the risk of any subsequent
HSIL high-grade disease of the cervix (20.1 to 86.3%)
[28]. Similarly, post-hoc analysis of the PATRICIA trial
of the bivalent vaccine showed that of the total vacci-
nated cohort of 18,644 women, 454 (vaccine = 190,
control = 264) underwent an excisional procedure during
the trial. The efficacy 60 days or more post-excision sur-
gery for the first lesion, irrespective of HPV DNA re-
sults, was 88.2% (95% CI: 14.8, 99.7) against CIN2+.
Hence, women who undergo cervical excision surgical
therapy for cervical lesions after vaccination with the
first-generation HPV vaccines may continue to benefit
from vaccination, with a reduced risk of developing sub-
sequent CIN2+ [29].
The first study to examine vaccination in women
undergoing treatment for CIN2+ was performed at the
Department of Obstetrics and Gynecology of Chonnam
National University Hospital, Gwangju, Republic of
Korea (CNUH), between August 2007 and July 2010
[30]. Patients aged 20–45 years who were diagnosed with
CIN2+ and treated by LEEP were followed: 360 patients
were vaccinated with the quadrivalent HPV vaccine, and
377 patients were followed without vaccination. Irre-
spective of the causal HPV type, 36 (4.9%) patients de-
veloped recurrence: 9 vaccinated patients (2.5%) versus
27 non-vaccinated patients (7.2%). Multivariate analysis
showed that not being vaccinated after LEEP was an in-
dependent risk factor for recurrent CIN2+ (HR = 2.840;
95% CI 1.335–6.042; P < 0.01) [30].
A prospective clinical study (SPERimentazione ANti
HPV Zona Apuana (SPERANZA)) was designed to
evaluate whether vaccination after LEEP surgical treat-
ment in women with high-grade CIN could reduce the
risk of clinical disease relapse [31]. The quadrivalent
HPV vaccination of women undergoing treatment surgi-
cal therapy for CIN2+ cervical lesions and the Inter-
national Federation of Gynaecology and Obstetrics
(FIGO) stage IA1 cervical cancer reduced the risk of re-
current disease by 80%, suggesting a role as an adjuvant
beneficial role of vaccination to surgical treatment [31].
Although data concerning non-routine HPV vaccin-
ation in populations with a high risk of HPV infection
and associated lesions are scarce, multidisciplinary,
evidence-based consensus guidelines for HPV vaccin-
ation in high-risk populations were developed in Spain
[32]. A strong recommendation for HPV vaccination
was made in the following groups: human immunodefi-
ciency virus (HIV)-infected patients aged 9–26 years;
MSM aged 9–26 years; women with precancerous cer-
vical lesions; patients with congenital bone marrow fail-
ure syndrome; women who received a solid organ
transplant or haematopoietic stem cell transplantation
aged 9–26 years; and patients diagnosed with recurrent
respiratory papillomatosis aged 9–26 years. In the case
of women with precancerous cervical lesions, the vaccine
can be provided at any time but preferentially at diagno-
sis or before treatment. It is not recommended to per-
form an HPV test before vaccination because the
vaccine should be provided regardless of the HPV status
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[32]. These guidelines were adopted by the Spanish gov-
ernment in July 2018.
At the Hospital Clinic Barcelona, Spain, 265 women
were treated for CIN2+ between July 2013 and July
2018. All were offered vaccination: the rate of accept-
ance was 37% when the vaccine was not funded (HPV
vaccine after treatment was funded in July 2017) 75%
when women were offered free vaccination 1–12months
after treatment, and 84% when women were immediately
referred for free-of-cost vaccination after diagnosis [33].
Persistent or recurrent disease was diagnosed in 5/153
(3.3%) of the vaccinated women, whereas 12/112 (10.7%)
of the women who rejected HPV vaccination were diag-
nosed with persistent or recurrent disease (p = 0.015).
The protective effect of the HPV vaccine was particularly
clear in women who had no disease (negative HPV test,
negative Pap test, and, when performed, a negative bi-
opsy) in the first post -excisional treatment examination
at 6 months: none of the vaccinated women who were
free of disease in the first post conization examination
developed HSIL during follow-up, confirming that vac-
cination prevented the acquisition of new HPV infec-
tions after treatment. The women who had persistent
low-grade squamous intraepithelial lesion (LSIL)//HPV
infection in the first post-excision conization control
also tended to have lower rates of persistent/recurrent
HSIL at the end of follow-up when vaccinated, although
the differences were not statistically significant (6.9% vs.
14.0%, p = 0.173 in vaccinated and non-vaccinated pa-
tients, respectively).
While vaccination-induced antibodies prevented new
HPV infections in older women, it is unclear whether
they also prevented the reactivation of latent, previously
acquired infections, as may occur due to immune senes-
cence in older age or specific immunosuppression. Also,
the role of reactivation in clinically relevant cervical le-
sions needs further research.
HPV vaccination in relation to conization: a Danish
nationwide study
In Denmark, all citizens have a personal identification
number, which is used universally in society, making it
possible to perform population-based surveillance stud-
ies with virtually no loss to follow-up. This study linked
data from the Pathology Data Bank to those in the HPV
vaccination register, leading to a study population of
three groups of women treated for CIN3: 15,054 unvac-
cinated women, 399 women vaccinated up to 3 months
before treatment, and 1675 women vaccinated up to 12
months after treatment [34]. These women were
followed up for the development of CIN2+. While there
was little difference between the absolute risk of CIN2+
between the unvaccinated and the group vaccinated after
treatment, the risk was consistently lower for women
vaccinated before treatment, and the risk diverged 5
years after treatment (Fig. 1). However, this decreased
HR (0.77; 0.45–1.32) was not statistically significant.
Transmission reduction and prevention with HPV
vaccination (TRAP-HPV) study
To study the effect of vaccination on HPV transmission
within stable couples, data from the HPV Infection and
Transmission among Couples through Heterosexual ac-
tivity (HITCH) study [35], a prospective cohort study of
heterosexual couples (women ages 18–24 years) in
Montreal from 2005 to 2013 were used. Among 497
couples, 12, 16, and 35 women received 1, 2, or 3 vaccin-
ation doses at baseline, respectively, with a median age
at vaccination of 18 years. Most of these women (92%)
had their first coitus before HPV vaccination. At base-
line, partner concordance of persistent vaccine-type
(VT) infections was lower in vaccinated women than in
unvaccinated women [adjusted odds ratio (aOR) = 0.10;
95% CI 0.01–0.65] but not for non-VT infections (aOR =
1.00; 95% CI 0.44–2.29) [36]. The incidence of persist-
ent VT infections in women was inversely associated
with the vaccination status at baseline (adjusted HR =
0.12; 95% CI 0.03–0.47). Likewise, male partners of vac-
cinated women had a lower incidence of VT infections
(aOR = 0.22; 95% CI 0.05–0.95). Finally, vaccinated
women with VT infections had significantly lower viral
loads than unvaccinated women (P = 0.001) [36]. These
data show that the vaccination of sexually active women
significantly reduced the transmission of VT HPV types
in heterosexual couples.
To determine the efficacy of an HPV vaccine in
reducing the transmission of genital and oral HPV infec-
tion to sexually active heterosexual partners of HPV-
vaccinated individuals, a randomized clinical trial was
set up (NCT01824537) [37]. The trial has a 2 × 2 factor-
ial design, vaccinating both male and female partners
with 9-valent HPV vaccine Gardasil 9, both with a pla-
cebo (hepatitis A vaccine), males with an HPV vaccine
and females with a placebo, and vice versa, aiming for a
sample size of 500 couples. Recruitment has been on-
going since January 2014, but the target number has
been hard to reach. This is the first RCT to investigate
HPV transmission reduction via vaccination within cou-
ples, which could provide empirically derived estimates
for health economic models and mathematical models
predicting herd immunity.
Predicting cohort-specific cervical cancer incidence from
population-based HPV prevalence surveys
The direct assessment of the time lag between HPV in-
fection acquisition and cervical cancer occurrence is un-
ethical. The uncertainty about the time lag may affect
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the validity of the cervical cancer risk estimates and of
the expected impact of preventive measures.
Therefore, an attempt was made to estimate cervical
cancer incidence rates in hr-HPV-positive women as a
function of the time lag between a hr-HPV prevalence
measurement (exposure) and cervical cancer detection
(outcome). Based on this analysis, it may be possible to
make longitudinal and cohort-specific projections of cer-
vical cancer incidence from age-specific hr-HPV preva-
lence data. An additive Poisson regression model
without an intercept term was used to comply with the
restriction that cervical cancer rates should be zero if
the HPV prevalence is zero. Using the average age at
sexual debut, by birth cohort and by location, cervical
cancer incidence projections could be made. These pro-
jections flattened from age 35 onwards. Moreover, the
impact of the mean age at sexual debut was strongest in
younger age groups.
The effect of hr-HPV prevalence on annual cervical
cancer incidence among HPV+ women increased with
the age at HPV detection and the time lag between hr-
HPV prevalence and cancer incidence assessment. Fur-
thermore, below age 35, cervical cancer risk changed
based on the average age at first sexual encounter, which
is a proxy for the HPV infection duration. Both findings
are consistent with the current biological model of HPV
progression to cervical cancer. This allows short-term
predictions of the annual cancer incidence from HPV
prevalence data (which are relatively easy to collect) in
countries without cancer registration.
Overview of health economics models for HPV
vaccination in middle-aged adults
The United States Food and Drug Administration
(FDA) approved expanding the age indication for the
9-valent HPV vaccine to age 45 in October 2018.
Therefore, there is a need to perform cost-
effectiveness analyses of middle-aged adult vaccin-
ation, more specifically, the cost-effectiveness of HPV
vaccination for females (and possibly males) between
ages 27 and 45. Five models were used to inform
adult HPV vaccination policy decisions in the US: the
HPV-ADVISE model (Laval University/ Centers for
Disease Control and Prevention (CDC); a simplified
model (CDC); the Merck model; the Harvard model;
and the Policy1-Cervix model (Cancer Council New
South Wales). All five models include a wide range of
health outcomes (cervical precancers; cervical, anal,
vaginal, vulvar, penile, and oropharyngeal cancers; and
anogenital warts), all account for herd effects and
examine a long time period (~ 100 years).
However, the models differ in structure, calibration,
cervical cancer screening assumptions,
Fig. 1 Absolute risk of CIN2+ by follow-up time according to vaccination status . Absolute risk of cervical intraepithelial neoplasia grade 2 or
worse during follow-up for women not vaccinated in relation to conization and women vaccinated 0–3 months before (a) and 0–12 months after
conization (b). Follow-up starts 1 year after conization. The number of women at risk is given in the risk-tables below each panel. Source: Sand,
F.L., Kjaer, S.K., Frederiksen, K. and Dehlendorff, C. (2020), Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to
HPV vaccination status. Int. J. Cancer, 147: 641–647(https://doi.org/10.1002/ijc.32752)
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vaccine uptake assumptions for middle-aged adults,
the natural history of HPV parameters, HPV transmis-
sion dynamics, and cost and quality of life assumptions.
Routine vaccination at ages 11 or 12 years with catch-
up vaccination through age 26 years for females and age
21 years for males was shown to be cost-effective in all
models, ranging from cost savings in the HPV-ADVISE
model to $34,600 per quality-adjusted life year (QALY)
gained versus no vaccination in the Harvard model. In
June 2019, the Advisory Committee on Immunization
Practices recommended to extend catch-up vaccination
for males through age 26 year, making it the same as the
existing recommendation for women.
The vaccination of adults up to the age of 45 would
prevent an additional 56,000 cases of CIN2/3 com-
pared to the 13,000,000 cases prevented by the
current recommendation (0.43%). Similarly, an add-
itional 3000 cases of cervical cancer compared to the
653,000 cases prevented by the current recommenda-
tion (0.46%); an additional 124,000 cases of anogenital
warts compared to the 32,000,000 cases prevented by
the current recommendation (0.39%); and an add-
itional 4000 cases of other HPV-related cancers com-
pared to the 769,000 cases prevented by the current
recommendation (0.52%) (Fig. 2) [38]. The cost per
QALY gained, based on the 5 models, would range
from $117,500 to $1,471,000 when extending the age
to 45. Assuming faster progression and lower natural
immunity, these figures would come down. However,
for the HPV-ADVISE model, they would remain over
$1,000,000 per QALY gained, while the figures would
only become worse assuming slower progression and
higher natural immunity.
In summary, the cost per QALY gained by the
current vaccination programme is below $35,000 in all
models and even lead to cost savings in the HPV-ADVI
SE model, whereas adult vaccination is much less cost-
effective. Notable differences in cost-effectiveness esti-
mates exist across models, likely due to uncertainties in
HPV natural history and transmission dynamics, which
preclude a precise estimate of the cost-effectiveness of
vaccination in adults. Furthermore, the results were
more consistent when standardizing health economic
assumptions and assumptions regarding deaths due to
undiagnosed cancer. In the context of the existing
programme, vaccinating adults over 26 years of age
would produce relatively small additional health bene-
fits, with the number needed to vaccinate to prevent
one case of disease being approximately 40 times
higher.
Fig. 2 Estimated impact of adult HPV vaccination [38]. Source: Brisson ACIP, February 2019, CIN = cervical intraepithelial neoplasia; median
estimates generated by 50 best-fitting parameter sets
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HPV vaccination in high-risk groups
Directionality of HPV infection transmission in
heterosexual couples: a systematic review and meta-
analysis
In individual-based studies, researchers can determine
HPV prevalence and incidence rates by conducting mul-
tiple follow-up visits on the same study subjects.
Couple-based research could permit the examination of
transmission dynamics between partners, augmenting
the information collected in individual-based HPV trans-
mission research.
The EUropean Research Organisation on Genital
Infection and Neoplasia (EUROGIN) 2014 Roadmap
provided a descriptive overview of five heterosexual
couple-based longitudinal studies in its discourse of
HPV transmission rates, suggesting greater rates of
female-to-male (F-M) than male-to-female (M-F) trans-
mission. A systematic review and meta-analysis were
performed to assess the evidence for the differential
transmission rate hypothesis in couple-based studies in
regard to genital-to-genital HPV transmission [39].
Seven longitudinal studies on heterosexual couples in
whom genital samples were collected were included.
Several different HPV detection methods were used,
which may have impacted the study findings.
The overall rate difference was 0.61 infections per 100
person-months (95% CI -0.27-1.49), indicating that F-M
transmission is higher, although the result was not sig-
nificant, and substantial statistical heterogeneity existed
(I2 = 75%). Excluding two potential outliers did not alter
the rates significantly; F-M transmission was still
favoured. However, these findings must be interpreted
with caution due to the presence of substantial statistical
heterogeneity.
HPV vaccination for sex workers: finding a balance
between the pros and cons
A study including 304 female sex workers (SWs) in
Amsterdam, the Netherlands, showed that the vaginal
and anal hr-HPV prevalence were 46 and 55%, respect-
ively, whereas anti-HPV seropositivity, against a least
one of the high risk types included in the Gardasil 9 vac-
cine, was 37% [40]. This led to the hypothesis that HPV
vaccination of SWs, preferably at the initiation of sex
working, may be a useful prevention method against hr-
HPV infection, disease and potentially transmission.
Therefore, determinants of their intention to become
vaccinated against HPV were explored. Vaccination
intention was high but decreased significantly when vac-
cination would require out-of-pocket payment [41].
There are several reasons to offer HPV vaccinations to
SWs [42]: SWs are at a high risk for HPV infection; they
are unlikely to have been vaccinated in the past; the im-
munogenicity of vaccines is excellent in all women (even
if previously exposed); women with HPV disease may
still benefit from vaccination; SWs may not have been
exposed to all HPV types covered by HPV vaccines; and
vaccination may reduce the transmission of HPV to cli-
ents. On the other hand, there are also reasons not to
offer the vaccine to SWs: the current vaccines are
prophylactic and have not been shown to be thera-
peutic; it is difficult to establish a woman’s previous
HPV status, as more women may have been infected
than a DNA test or serology shows; it is difficult to
establish whether HPV was cleared or has gone into
latency; finally, vaccinating after sexual debut may not
offer protection against CIN2+ or anal intraepithelial
neoplasia (AIN2+)+) [7, 43].
Although HPV vaccination should be offered to all
girls prior to sexual debut, studies are needed to directly
or indirectly establish the effectiveness of vaccinating
SWs. Although RCTs generally provide the best answer,
these are not realistic in the current setting. Because
vaccines are safe, a benefit/risk balance is not needed,
and a cost-benefit balance will suffice.
Baseline HPV prevalence in rectal swabs from men
attending a sexual health clinic in Scotland: assessing the
potential impact of a selective HPV vaccination
programme for MSM
As MSM are at a high risk of HPV infection and associ-
ated disease and have little to no benefit from the girls-
only vaccination programme, a vaccination programme
was recommended for MSM attending sexual health
clinics in Scotland [44]. The programme was imple-
mented in July 2017 for MSM under 45 years of age as
well as prisoners and transgender women. The uptake of
the HPV vaccine in Scotland for MSM is approximately
65% for the first dose, but completion of the schedule is
much lower. Uptake is highest in the 20–29 age group.
To examine the impact on disease, data were extracted
from the national sexual health database on the number
of genital wart treatment prescriptions. While declines
could be seen in the numbers of prescriptions for both
women and in heterosexual men, this was not the case
for MSM. Similarly, rectal swabs were used to assess the
impact of vaccination on HPV prevalence, comparing
prevalence in samples taken before (n = 1209) and after
(n = 1235) the introduction of the program. This showed
a slight and non-significant increase in HPV-6/11 types
6 and 11 and a significant decrease in HPV-16/18 types
16 and 18 from 37.9 to 31.8% (odds ratio (OR) 0.76, p =
0.0014). Although it is an indication of an early vaccine
effect, confirmation will be necessary. Moreover, further
work is underway to link the vaccine status to genital
wart treatment prescribing data, HPV prevalence data,
and, in the long term, HPV-associated cancers.
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Limitations and elimination goals
Towards cervical cancer elimination: the context of HPV
vaccination
There is large global variability in cervical cancer inci-
dence rates, with exceptionally high rates in the African
region. However, even in regions with high incidence
rates, exceptions exist, such as La Reunion in Eastern
Africa and Niger in Western Africa, showing rates of ap-
proximately 10/100,000 women, which is well below the
rates in some countries in northern, southern and east-
ern Europe (Fig. 3).
Three HPV models, the Policy 1 model, the Harvard
model and the HPV-ADVISE model, as well as an HIV
model, the Spectrum model, were selected, as they are
dynamic models that include vaccination, screening and
treatment. These models were used to investigate three
scenarios. Scenario 1 is based on girls-only vaccination,
with no change in screening compared to the current
situation. Scenario 2 is based on girls-only vaccination,
with once-in-a-lifetime screening at 35 years of age. Sce-
nario 3 is based on girls-only vaccination, with two life-
time screens at 35 and 45 years of age. All scenarios are
based on HPV-based screening, 100% treatment efficacy,
10% loss to follow-up for screening and 90% coverage of
9 to 14-year olds, the lifelong duration of immunity, and
100% efficacy for 7 h-HPV types for the vaccine. While
all scenarios indicated that low-income countries (LICs)
will go below the 10/100,000 threshold, the 4/100,000
threshold was only reliably reached by scenario 3.
Looking at the cervical cancer incidence, the addition
of boys to the vaccination programme has shown little
impact in India, Vietnam and Nigeria and some impact
in Uganda, while catch-up vaccination up to the age of
25 has had no impact in any of these four countries.
These data have led to the development of a global strat-
egy directed towards the elimination of cervical cancer,
aiming for all countries to get below the incidence level of
4 cases/100,000 women. The 2030 targets set to achieve
this goal are as follows: 90% of girls fully vaccinated at the
age of 15; 70% of women screened with a high-precision
HPV-based test at the ages of 35 and 45; and treatment and
care for 90% of women with identified cervical disease.
Although 50% of all countries in the world have intro-
duced the HPV vaccine, this only covers approximately
30% of all girls globally. Furthermore, while 86% of HIC
and 58% of upper-middle-income countries (MICs) are
Fig. 3 Variability in cervical cancer incidence rates by world region. Source: WHO IVB Database, October 2019. Region: country with lowest
incidence – country with highest incidence. Southern Africa: Namibia – Swaziland; Eastern Africa: Fr. La Reunion – Malawi, Western Africa: Niger –
Guinea; Melanesia: New Caledonia – Papua New Guinea; Middle Africa: Gabon – Angola; South-Eastern Asia: Malaysia – Indonesia; Eastern Europe:
Poland – Moldavia; Caribbean: Puerto Rico – Jamaica; South America: Brazil – Bolivia; Micronesia/Polynesia: Fr. Polynesia – Guam; Southern Asia:
Iran – Maldives; Central America: Mexico – Belize; Eastern Asia: China – Mongolia; Northern Europe: Finland – Latvia; Southern Europe: Macedonia
– Bosnia Herzegovina; Northern Africa: Tunisia – Morocco; Western Europe: Switzerland – Belgium; Northern America: Canada – USA; Australia/
New Zealand: Australia; Western Asia: Qatar - Georgia
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covered, only 33% of lower MICs and 16% of LICs are
covered, which are the countries where the burden is the
highest.
There is an insufficient vaccine supply to meet the
overall demand of the Global Alliance for Vaccines and
Immunisation (GAVI) countries, although all planned
GAVI-supported HPV vaccine introductions are moving
ahead with routine cohorts, without room for multi-age
cohorts (catch-up). At least one MIC had to postpone
introduction in 2019 due to the lack of supply. The
supplies are expected to slowly grow over the next 1–3
years, followed by quicker growth in the mid- to long-
term. Several scenarios have been used to compare dose
requirements, including a 2-dose and a 1-dose schedule,
with or without catch-up vaccination, and extended
schedules with the second dose after 3 or 5 years. At a
base supply level, all scenarios experience a shortage in
the short term, with the 3-year extended interval being
least affected, but supplies will be adequate in the mid-
to long-term time period. However, in the case of low
supply, only 1-dose schedules will have adequate sup-
plies in the mid- to long-term, with the 3-year extended
interval as a possible alternative. The introduction of
catch-up programmes, including the vaccination of
adults, may lead to postponed introductions in 1–27
countries in the short term, leaving 45,000–143,000
girls/women vulnerable to cervical cancer. Some HICs
have already introduced gender-neutral vaccination,
which requires 9 million (M) doses or 18% of the global
demand. If other HICs add boys to the programme, this
will require another 4 million doses, which might mean
that introduction is delayed in 12 LMICs. This led to the
Strategic Advisory Group of Experts on Immunization
(SAGE) recommendation that countries should tempor-
arily postpone the implementation of gender-neutral,
older-age group (> 15 years) and multi-age cohort HPV
vaccination strategies until all countries have access to
the HPV vaccine. This will significantly relieve supply
constraints in the short term and enable the allocation
of doses to high-burden countries currently planning to
introduce this vaccine. It is important to note that the
above estimates were made prior to the coronavirus pan-
demic and so could not consider any reduction in vac-
cine uptake that might have resulted from interruptions
in school and clinic-based programs.
Plenary discussion
Several topics were discussed as part of the plenary ses-
sions in the meeting.
Could cervical smear (PAP) taking increase the risk of HPV
infections?
First, it was stressed that this is a purely scientific issue
and not a public announcement. The value of cervical
cancer screening is not in question: there is ample evi-
dence that screening has led to a decrease in the inci-
dence of cervical cancer as well as associated mortality
[45–47]. However, this does not preclude testing the
hypothesis that the rising incidence in adenocarcinoma
could be related to more aggressive sampling to include
endocervical cells in the sample. Nevertheless, alterna-
tive explanations for this increase were offered, including
changes in sexual behaviour. The progressive lowering
of the age of coitarche would lead to early HPV infec-
tions, which could also be a reason for the increase in
adenocarcinoma, as the immature cervix during adoles-
cence may be more susceptible to persistent HPV infec-
tion. The combination of sampling with the use of
carrageenan may significantly reduce the risk of infec-
tion. Multiple trials are ongoing to confirm this. Alterna-
tively, atraumatic self-sampling has been extensively
evaluated for HPV DNA-based testing and is being con-
sidered for screening programs [48].
The rationale for vaccinating middle-aged adults
The key question is what the risk of developing cancer
by the age of HPV infection acquisition is. What kind of
studies need to be done to find this answer? Can the on-
going trials be used to develop estimates for modeling,
providing a distribution of the risk by age of infection?
Alternatively, trials are needed to compare the risk of
development of precancerous lesions after vaccination in
middle-aged adults. Although it is known that most in-
fections occur soon after the start of sexual debut activ-
ity, 15–20% of infections occur after the mid-20s.
Although the impact of hormonal changes during
pregnancy on HPV infection is known, this is not the
case for menopause. A number of observational stud-
ies have shown a second peak in HPV prevalence in
older age [49].
The ethics of vaccination
There is a strong consensus it is unethical not to vaccin-
ate girls in general and in particular in LMICs: these are
the countries with the highest burden and where estab-
lishing and performing effective cervical cancer screen-
ing programs, as well as treatment, is much more
complicated. Hence, the vaccine is their best hope.
However, not giving boys a chance to be vaccinated
also has ethical implications.
Data from a number of countries, including the US,
show that the oropharyngeal cancer incidence is increas-
ing [50–55], and the majority of this cancer in some
countries is HPV-related, whereas other head and neck
cancers are not necessarily HPV-related, and this frac-
tion, mostly caused by tobacco and alcohol, is decreas-
ing. In some countries with effective cervical cancer
screening, oropharyngeal cancer incidence has surpassed
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cervical cancer incidence, and oropharyngeal cancer oc-
curs predominantly in males. However, it cannot be
ruled out that most oropharyngeal cancers occurring in
males could be prevented by the vaccination of females.
Currently, there are only limited data on impact on in-
fections available. However, in June 2020 the FDA ap-
proved: “Prevention of oropharyngeal and other head
and neck cancers caused by the HPV types targeted by
Gardasil 9” to the vaccine’s indications.
Vaccine supply
The pharmaceutical industry is trying to increase the
HPV vaccine supplies: Merck is increasing vaccine pro-
duction, GlaxoSmithKline Biologicals (GSK) is re-
opening its vaccine-producing factory, and the Innovax
bivalent vaccine has now been licensed in China. While
important, these developments would not be enough to
solve the immediate problem of shortages. The shortage
is foreseen to be resolved by 2023/2024.
Intradermal immunization may be an alternative strat-
egy to evaluate. It has been done for influenza at 1/10th
of the dose. This solution has also been contemplated
for polio and rabies vaccines. In some regions, e.g., east-
ern Europe, intradermal delivery is already quite com-
mon. However, proper intradermal delivery is more
difficult, and switching from intramuscular to intrader-
mal delivery will take time and requires effort.
Lessons learned
 Older cohorts can be vaccinated for different
purposes: 1) to benefit the community by reducing
transmission or healthcare costs; 2) to benefit the
individual, although the latter might be limited in
older cohorts based on the studies reviewed during
the meeting.
 If vaccinating entire older cohorts is not possible
considering the higher costs or shortage of vaccine
supply, the focus could be on high-risk groups, such
as MSM or HIV+ women.
 Evidence is accumulating that the vaccination of
women with CIN2+ before or after treatment
reduces disease recurrence of disease. Provision of
the vaccine treatment should be considered,
regardless of age.
 Two sites are available to block HPV infection by
antibodies: 1) the binding of the virus to the
basement membrane and 2) the binding of the virus
to L1 binding sites on keratinocytes for transport
into the cell.
 To protect against HPV infection, low levels of
antibodies may be sufficient, but maybe high avidity
is necessary.
 Given the preventive effect of carrageenan, its use as
a standard lubricant during pelvic exams should be
considered. Three trials using carrageenan are
currently underway; preliminary results show that it
is 40% efficacious as a general use vaginal gel against
incident HPV infection.
 The priority for HPV vaccination lies with the target
groups: to achieve high coverage in girls and boys
between 9 and 14 years of age first.
 The vaccination of boys is not just focused on cervical
cancer prevention; it is also directed at several HPV-
related cancers that also occur in men. For instance,
in many HICs, there has been a steady increase in the
number of HPV-related oropharyngeal cancers, with
the HPV-related cancer burden in men approaching
that in women. Furthermore, gender-neutral vaccin-
ation may be a way to increase protection against all
HPV-associated cancers in countries with lower vac-
cination coverage in females.
 To date, the goals and policies for HPV vaccination
have been focused on benefits for vaccinated
individuals. It may be necessary to think more
broadly: by blocking transmission, a rapid drop in
HPV prevalence may be achieved.
 It may be too early to think about the elimination of
cervical cancer. We should aim to increase HPV
vaccination coverage in countries with the highest
cervical cancer incidence first, even if formal
elimination will only be possible if vaccination is
combined with screening and treatment, which may
be too costly for many LMICs.
 The impact of a pause/delay in the use of a valuable
vaccine should not be underestimated. Anti-vaccine
messaging can have a large negative effect on vac-
cine acceptance in both HICs and LMICs; therefore,
these must be strongly countered.
 If the goal truly is to eliminate cervical cancer as a
major public health problem, we need to immunize
whole populations, analogous to the polio
eradication effort. However, the eradication of
cervical cancer may not be achieved: a rate of less
than 4/100,000 women is not eradication of the
cancer or the underlying HPV infections.
We have to think globally, as the need for vaccines in
HICs, MICs, and LICs is the same, with younger cohorts
as a priority. However, we should not overlook the po-
tential benefits such as reduced costs of screening pro-
grams it can offer in the future.
Many evidence gaps exist, making further studies ne-
cessary. The following studies were suggested:
 Now that more data are available, revisit the efficacy
of HPV vaccination in older women
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 Investigate the impact of HPV vaccination on
reducing transmission with tissue culture
experiments, demonstrating that shed virus can be
neutralized or with RCTs showing a reduced risk of
transmission
 Develop more sensitive assays to detect mucosal
anti-HPV antibodies and use these assays in combin-
ation with standardized sample collection to increase
comparability between studies
 Investigate the risk of progress to cervical cancer
development after primary HPV acquisition at
different ages
 Develop RCTs to investigate the collection of
cytology samples in the presence or absence of
carrageenan
 Based on large data sets, including HPV genotyping
on cytology samples, after a change in sampling
device: look for an effect on glandular disease before
and after the new device
 Identify a small, not previously vaccinated
population, preferably on an island, and give
everybody a single dose of vaccine. This should have
a profound impact on transmission. At the same
time, it may be possible to assess the potential for
elimination
 Given the shortage in vaccine supply, intradermal
immunization to save VLPs should be considered, so
that a delay in vaccination in LMICs may be
avoided. While switching to intradermal
administration will take time and effort, it may be
useful for other antigens at a later point (e.g.,
pandemic influenza)
 Studies will have to be conducted to look at the
effectiveness of the vaccination of SWs, both for
SWs themselves (disease prevention) and for society,
by reducing transmission from a potential reservoir
 Further studies are needed to substantiate the
evidence that vaccination after excision of pre-
cancerous lesions helps to reduce the persistence
and/or recurrence of the lesions.
Conclusion
Based on the data presented and the discussion that took
place, it can be concluded that it is premature to intro-
duce routine vaccination of adults, as the information is
incomplete and many further studies are needed (see
above) to fill the knowledge gaps.
Given the limited HPV vaccine supply in the short
term, the vaccination of adults should not consume
vaccine doses. Vaccination of younger age cohorts re-
mains the priority, especially in LMICs, as these are
the countries with the highest burden of HPV-
associated cancers.
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